

31 December 2024

Privatisation by way of merger

Disclosure of dealings in the shares of Shanghai Henlius Biotech, Inc.

The Executive received the following disclosure of securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers:

| Party | Date | Description of relevant securities | Description of products | Nature of dealings | Number of reference securities to which the derivatives relate | Maturity date / closing out date | Reference price | Total amount paid / received | Resultant balance (including those of any person with whom there is an agreement or understanding) |
|--------------------------------|------------------|------------------------------------|-------------------------|--------------------------------------|--|----------------------------------|-----------------|------------------------------|--|
| CICC Financial Trading Limited | 30 December 2024 | Derivatives | Other types of products | Closing out of a derivative contract | 700 | 22 January 2025 | \$23.8354 | \$16,684.7800 | 240,800 |
| | | Derivatives | Other types of products | Closing out of a derivative contract | 700 | 3 January 2026 | \$23.8702 | \$16,709.1400 | 240,800 |

End



Note:

CICC Financial Trading Limited is an exempt principal trader connected with the Offeror.

Dealings were made for its own account.

CICC Financial Trading Limited is ultimately owned by China International Capital Corporation Limited.